Unlock this StockReport nowClick to Unlock

A1M Pharma AB Share Price

A1M TO SEK0.95 0.0  3.3%

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed 1 / 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 TTM 2019E 2020E CAGR / Avg
Revenue SEKm
Operating Profit SEKm
Net Profit SEKm
EPS Reported SEK
EPS Normalised SEK
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps SEK
Capex ps SEK
Free Cashflow ps SEK
Dividend ps SEK
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc SEKm
Working Capital SEKm
Net Fixed Assets SEKm
Net Debt SEKm
Book Value SEKm
Average Shares m
Book Value ps SEK

FINANCIAL BRIEF: For the three months ended 31 March 2019, A1M Pharma AB revenues was not reported. Net loss decreased 8% to SEK13.9M. Lower net loss reflects Research & Development expenses decrease of 9% to SEK10.8M (expense), Selling Expenses decrease of 28% to SEK936K (expense), Administrative Expenses decrease of 6% to SEK1.3M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -SEK1.02 to -SEK0.13. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score  
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Mar '19) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2019
31st Dec 2020

Price Target: SEK6.44
(+6001% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (SEK) (SEK) (SEK) (SEK) (SEK) (SEK)
Consensus Estimate
1m Change
3m Change
1 broker Broker Consensus Trend
Broker Recommendations for A1M Pharma AB
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
There are no named brokers.

Profile Summary

A1M Pharma AB is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.

Directors: Cristina Glad (CHM) 67, Tobias Larsson Agervald (CEO) , Fredrik Werner (CFO) , Magnus Gram (CSO) , Elisabeth Augustsson (OTH) 54, Fredrik Lehmann (OTH) 43, Ronny Renfurm (OTH) , Goran Forsberg (DRC) 56, Johannes Hulthe (DRC) ,

No. of Employees: 14 No. of Shareholders: n/a

Last Annual December 31st, 2018
Last Interim March 31st, 2019
Incorporated April 4, 2008
Public Since April 3, 2013
Shares in Issue 103,734,196
Free Float 102.7m (99.0%)
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OMX Nordic Exchange Stockholm (Dual Listing)
Eligible for an ISA? a SIPP?

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.

Should you buy A1M TO

Access A1M TO Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis